Austar Lifesciences (HKG:6118) expects to record an attributable profit of not less than 30 million yuan for 2025, up from about 16 million yuan a year earlier, according to a Friday Hong Kong bourse filing.
The company attributed the increase mainly to lower operating expenses, including reduced administrative and research and development costs, as well as higher other gains, driven largely by exchange gains, and lower finance costs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.